A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
21/03/2022at 13:53

Boehringer Ingelheim and Saniona schizophrenia partnership advances to next stage

The firms are ready to take their two-year long collaboration to the next level.
Photo: Saniona / PR
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

Boehringer Ingelheim and Saniona are advancing to the next stage of their partnership on a drug candidate within the schizophrenia indication, the latter firm announces in a press release on Monday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Johan Luthman, head of research and development at Lundbeck | Photo: PR / Lundbeck

    Lundbeck parks Alzheimer's drug hope as there is no evidence it works

    For subscribers

  • Photo: Saniona / PR

    Saniona clears obstacle ahead of new trial

    For subscribers

  • Photo: Thomas Borberg

    FDA approves Lundbeck's schizophrenia treatment for teenagers

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Pharma & biotech

Eli Lilly seeking chronic kidney disease approval with Jardiance

The FDA has accepted an application from the US-based pharmaceutical company to expand the indication of diabetes drug Jardiance to include chronic kidney disease.

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

FDA approves Novo Nordisk's Rybelsus as first-line treatment option

Rybelsus, the tablet formulation of semaglutide, has now been approved in the US as a first-line treatment option for adults with type 2 diabetes.

For subscribers

Foto: Ey / Pr
Pharma & biotech

Gubra could go public before summer, says media

The biotech company and contract research organization has made preparations for an initial public offering this year, reports Inside Business.

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Application Manager

  • Experienced Patent Counsel

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Commercial Director

  • Lead Data Architect

  • Head of Regulatory Affairs Danmark

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Principal Laboratory Technologist

See all jobs

Jobs

  • Senior Regulatory Affairs Professional

  • Clinical Operational Associate

  • Application Manager

  • Experienced Patent Counsel

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Sr. Director, Drug Safety Physician

  • Head of International Sales

  • Commercial Director

  • Lead Data Architect

  • Head of Regulatory Affairs Danmark

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Application Manager

  • Principal Laboratory Technologist

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge